WO2016075661A1 - Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions - Google Patents

Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions Download PDF

Info

Publication number
WO2016075661A1
WO2016075661A1 PCT/IB2015/058774 IB2015058774W WO2016075661A1 WO 2016075661 A1 WO2016075661 A1 WO 2016075661A1 IB 2015058774 W IB2015058774 W IB 2015058774W WO 2016075661 A1 WO2016075661 A1 WO 2016075661A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
pharmaceutically acceptable
treatment
formula
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2015/058774
Other languages
English (en)
French (fr)
Inventor
Helene G. Bazin-Lee
Yufeng Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES15797460T priority Critical patent/ES2917887T3/es
Priority to EP15797460.1A priority patent/EP3218377B1/en
Priority to JP2017525536A priority patent/JP2017533925A/ja
Priority to US15/526,345 priority patent/US10584125B2/en
Priority to BR112017009648A priority patent/BR112017009648A2/pt
Priority to CA2967248A priority patent/CA2967248A1/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to CN201580071475.2A priority patent/CN107108628A/zh
Priority to MX2017006302A priority patent/MX2017006302A/es
Publication of WO2016075661A1 publication Critical patent/WO2016075661A1/en
Anticipated expiration legal-status Critical
Priority to US16/745,569 priority patent/US10919894B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Definitions

  • the innate immune system recognises microbes via a limited number of germline-encoded Pattern-Recognition Receptors (PRRs) which have a number of important characteristics.
  • PRRs Pattern-Recognition Receptors
  • the compound 6-amino- 9-[5-(4-piperidinyl)pentyl]-2-[(l S)-l-methylbutyl]oxy]-7,9-dihydro-8H-purin-8-one, or a pharmaceutically acceptable salt thereof, for use in therapy it will be appreciated that, when the compound 6-amino-9-[5-(4-piperidinyl)pentyl]-2-[(l S)-l- methylbutyl]oxy]-7,9-dihydro-8H-purin-8-one, or a pharmaceutically acceptable salt thereof, is used in therapy, it is used as an active therapeutic agent.
  • a vaccine composition comprising an antigen or antigen composition and the compound 6-amino-9-[5-(4-piperidinyl)pentyl]-2-[(l S)- l-methylbutyl]oxy]-7,9-dihydro-8H-purin-8-one, or a pharmaceutically acceptable salt thereof.
  • references herein to compounds of the invention mean a compound of formula (I) as the free base, or as a salt, for example a pharmaceutically acceptable salt.
  • One or more tonicity-adjusting agent(s) may be included to achieve tonicity with body fluids e.g. fluids of the nasal cavity, resulting in reduced levels of irritancy.
  • pharmaceutically acceptable tonicity adjusting agents include, but are not limited to, sodium chloride, dextrose, xylitol, calcium chloride, glucose, glycerine and sorbitol.
  • a tonicity-adjusting agent, if present, may be included in an amount of from 0.1 to 10%) (w/w), such as from 4.5 to 5.5% (w/w), for example about 5.0% (w/w), based on the total weight of the composition.
  • the compounds of formula (I) and pharmaceutically acceptable salts thereof may, for example, be formulated for transdermal delivery by composition into patches or other devices (e.g. pressurised gas devices) which deliver the active component into the skin.
  • devices e.g. pressurised gas devices
  • the compounds of formula (I) and pharmaceutically acceptable salts thereof may be employed alone or in combination with other therapeutic agents.
  • the compounds of formula (I) and pharmaceutically acceptable salts thereof and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately, administration may occur simultaneously or sequentially, in any order.
  • the amounts of the compound(s) of formula (I) or pharmaceutically acceptable salt(s) thereof and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.
  • the administration of a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof with other treatment agents may be in combination by administration concomitantly in a unitary pharmaceutical composition including both compounds, or in separate pharmaceutical compositions each including one of the compounds.
  • the combination may be administered separately in a sequential manner wherein one treatment agent is administered first and the other second or vice versa. Such sequential administration may be close in time or remote in time.
  • Example 5 Assay for the Induction of Interferon-alpha and TNF-alpha using Fresh Human Peripheral Blood Mononuclear Cells (PBMCs)
  • PBMCs Fresh Human Peripheral Blood Mononuclear Cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/IB2015/058774 2014-11-13 2015-11-13 Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions Ceased WO2016075661A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP15797460.1A EP3218377B1 (en) 2014-11-13 2015-11-13 Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
JP2017525536A JP2017533925A (ja) 2014-11-13 2015-11-13 アレルギー性疾患又は他の炎症状態の治療に有用なアデニン誘導体
US15/526,345 US10584125B2 (en) 2014-11-13 2015-11-13 Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
BR112017009648A BR112017009648A2 (pt) 2014-11-13 2015-11-13 composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
CA2967248A CA2967248A1 (en) 2014-11-13 2015-11-13 Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
ES15797460T ES2917887T3 (es) 2014-11-13 2015-11-13 Derivados de adenina que son útiles en el tratamiento de enfermedades alérgicas u otras afecciones inflamatorias
CN201580071475.2A CN107108628A (zh) 2014-11-13 2015-11-13 可用于治疗变应性疾病或其它炎性病症的腺嘌呤衍生物
MX2017006302A MX2017006302A (es) 2014-11-13 2015-11-13 Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
US16/745,569 US10919894B2 (en) 2014-11-13 2020-01-17 Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462079027P 2014-11-13 2014-11-13
US62/079,027 2014-11-13

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/526,345 A-371-Of-International US10584125B2 (en) 2014-11-13 2015-11-13 Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
US16/745,569 Division US10919894B2 (en) 2014-11-13 2020-01-17 Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions

Publications (1)

Publication Number Publication Date
WO2016075661A1 true WO2016075661A1 (en) 2016-05-19

Family

ID=54601865

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/058774 Ceased WO2016075661A1 (en) 2014-11-13 2015-11-13 Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions

Country Status (10)

Country Link
US (2) US10584125B2 (https=)
EP (1) EP3218377B1 (https=)
JP (1) JP2017533925A (https=)
CN (1) CN107108628A (https=)
BE (1) BE1023340B1 (https=)
BR (1) BR112017009648A2 (https=)
CA (1) CA2967248A1 (https=)
ES (1) ES2917887T3 (https=)
MX (1) MX2017006302A (https=)
WO (1) WO2016075661A1 (https=)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017222611A (ja) * 2016-06-16 2017-12-21 学校法人上智学院 ピペリジン化合物の製造方法
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
WO2019193543A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
WO2019193542A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides
WO2019193533A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2'-cyclic dinucleotides
WO2019200247A1 (en) 2018-04-12 2019-10-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
WO2020092621A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US10646566B2 (en) 2015-03-10 2020-05-12 Glaxosmithkline Biologicals S.A. Compositions and uses
US10662416B2 (en) 2016-10-14 2020-05-26 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020214652A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020214663A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN118165930A (zh) * 2024-04-16 2024-06-11 颖奕干细胞生物科技(海南)有限公司 一种长效维持血液中颗粒球细胞的方法
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017006302A (es) * 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
EP4198031A1 (en) * 2016-08-08 2023-06-21 Merck Patent GmbH Tlr7/8 antagonists and uses thereof

Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021229A1 (en) 1993-03-17 1994-09-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
WO1998034596A2 (en) 1997-02-07 1998-08-13 Minnesota Mining And Manufacturing Company Biocompatible compounds for pharmaceutical drug delivery systems
EP1065213A2 (en) 1999-07-02 2001-01-03 Japan Tobacco Inc. HCV polymerase suitable for crystal structure analysis and method for using the enzyme
WO2001047883A1 (fr) 1999-12-27 2001-07-05 Japan Tobacco Inc. Composes a cycles accoles et leur utilisation comme medicaments
WO2002004425A2 (en) 2000-07-06 2002-01-17 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
WO2002057287A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2002057245A1 (en) 2001-01-19 2002-07-25 Arco Chemical Technology, L.P. Epoxidation catalyst and process
WO2002074769A1 (en) 2001-03-19 2002-09-26 Ono Pharmaceutical Co., Ltd. Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
WO2003000254A1 (fr) 2001-06-26 2003-01-03 Japan Tobacco Inc. Composes cycliques condenses et utilisations medicales de ceux-ci
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
WO2003085375A2 (en) 2002-04-04 2003-10-16 Achillion Pharmaceuticals, Inc. Hcv antiviral and cytotoxicity drug screening assay
WO2003095441A1 (en) 2002-05-10 2003-11-20 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
WO2004037818A1 (en) 2002-10-24 2004-05-06 Glaxo Group Limited 1-acyl-pyrrolidine derivatives for the treatment of viral infections
WO2004055010A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclopropyl compounds as ccr5 antagonists
WO2004055011A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
WO2004054581A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
WO2004055016A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Pyrrolidine and azetidine compounds as ccr5 antagonists
WO2004055012A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Indane compounds as ccr5 antagonists
WO2004054974A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
WO2004064925A1 (en) 2003-01-22 2004-08-05 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2004065367A1 (en) 2003-01-22 2004-08-05 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2004074270A2 (en) 2003-02-21 2004-09-02 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
WO2005044354A1 (en) 2003-11-03 2005-05-19 Glaxo Group Limited A fluid dispensing device
WO2005080388A1 (en) 2004-02-20 2005-09-01 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2005105761A1 (en) 2004-04-28 2005-11-10 Arrow Therapeutics Limited Morpholinylanilinoquinazo- line derivatives for use as antiviral agents
WO2006020082A1 (en) 2004-08-09 2006-02-23 Bristol-Myers Squibb Company Inhibitors of hcv replication
WO2006018725A1 (en) 2004-08-18 2006-02-23 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
WO2006045613A1 (en) 2004-10-25 2006-05-04 Glaxo Group Limited 4-methoxymethyl-pyrrolidine-2-carboxylic acid compounds and derivatives thereof as hepatitis c virus inhibitors
WO2006122011A2 (en) 2005-05-09 2006-11-16 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
WO2007034882A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
WO2007138084A2 (en) 2006-05-30 2007-12-06 Glaxo Group Limited Fluid dispenser
US20090061867A1 (en) 1996-12-24 2009-03-05 Moore Michael P Method for controlling channel re-selection
WO2010018134A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Novel adenine derivatives
WO2010048520A1 (en) 2008-10-24 2010-04-29 Glaxosmithkline Biologicals Sa Lipidated imidazoquinoline derivatives
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065372A1 (es) * 2007-02-19 2009-06-03 Smithkline Beecham Corp Derivados de purina
BRPI0917458A2 (pt) * 2008-08-11 2015-12-01 Glaxosmithkline Llc composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
UA103195C2 (uk) * 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
RS53347B (sr) * 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
MX2012001524A (es) 2009-08-07 2012-02-29 Glaxosmithkline Biolog Sa Derivados de oxoadenina lipidada.
DK2534149T3 (da) * 2010-02-10 2015-01-05 Glaxosmithkline Llc 6-amino-2-{ [ (1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-on-maleat
MX2017006302A (es) * 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.

Patent Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021229A1 (en) 1993-03-17 1994-09-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US20090061867A1 (en) 1996-12-24 2009-03-05 Moore Michael P Method for controlling channel re-selection
WO1998034596A2 (en) 1997-02-07 1998-08-13 Minnesota Mining And Manufacturing Company Biocompatible compounds for pharmaceutical drug delivery systems
EP1065213A2 (en) 1999-07-02 2001-01-03 Japan Tobacco Inc. HCV polymerase suitable for crystal structure analysis and method for using the enzyme
WO2001047883A1 (fr) 1999-12-27 2001-07-05 Japan Tobacco Inc. Composes a cycles accoles et leur utilisation comme medicaments
WO2002004425A2 (en) 2000-07-06 2002-01-17 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
WO2002057245A1 (en) 2001-01-19 2002-07-25 Arco Chemical Technology, L.P. Epoxidation catalyst and process
WO2002057287A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2002074769A1 (en) 2001-03-19 2002-09-26 Ono Pharmaceutical Co., Ltd. Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
WO2003000254A1 (fr) 2001-06-26 2003-01-03 Japan Tobacco Inc. Composes cycliques condenses et utilisations medicales de ceux-ci
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
WO2003085375A2 (en) 2002-04-04 2003-10-16 Achillion Pharmaceuticals, Inc. Hcv antiviral and cytotoxicity drug screening assay
WO2003095441A1 (en) 2002-05-10 2003-11-20 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
WO2004037818A1 (en) 2002-10-24 2004-05-06 Glaxo Group Limited 1-acyl-pyrrolidine derivatives for the treatment of viral infections
WO2004054974A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
WO2004055010A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclopropyl compounds as ccr5 antagonists
WO2004055016A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Pyrrolidine and azetidine compounds as ccr5 antagonists
WO2004055012A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Indane compounds as ccr5 antagonists
WO2004055011A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
WO2004054581A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
WO2004064925A1 (en) 2003-01-22 2004-08-05 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2004065367A1 (en) 2003-01-22 2004-08-05 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2004074270A2 (en) 2003-02-21 2004-09-02 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
US20050176701A1 (en) 2003-02-21 2005-08-11 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
WO2005044354A1 (en) 2003-11-03 2005-05-19 Glaxo Group Limited A fluid dispensing device
WO2005080388A1 (en) 2004-02-20 2005-09-01 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2005105761A1 (en) 2004-04-28 2005-11-10 Arrow Therapeutics Limited Morpholinylanilinoquinazo- line derivatives for use as antiviral agents
WO2006020082A1 (en) 2004-08-09 2006-02-23 Bristol-Myers Squibb Company Inhibitors of hcv replication
WO2006018725A1 (en) 2004-08-18 2006-02-23 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
WO2006045613A1 (en) 2004-10-25 2006-05-04 Glaxo Group Limited 4-methoxymethyl-pyrrolidine-2-carboxylic acid compounds and derivatives thereof as hepatitis c virus inhibitors
WO2006122011A2 (en) 2005-05-09 2006-11-16 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
WO2007034882A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
WO2007138084A2 (en) 2006-05-30 2007-12-06 Glaxo Group Limited Fluid dispenser
WO2010018134A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Novel adenine derivatives
WO2010048520A1 (en) 2008-10-24 2010-04-29 Glaxosmithkline Biologicals Sa Lipidated imidazoquinoline derivatives
US8624029B2 (en) 2008-10-24 2014-01-07 Glaxosmithkline Biologicals S.A. Lipidated imidazoquinoline derivatives
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
AKIRA ET AL., NAT REV IMMUNOL, vol. 4, 2004, pages 499 - 511
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
DIEBOLD S.S. ET AL., SCIENCE, vol. 303, 2004, pages 1529 - 1531
GERSTER ET AL., J.MED.CHEM., vol. 48, 2005, pages 3481 - 3491
HEIL ET AL., EUR. J.IMMUNOL., vol. 33, 2003, pages 2987 - 2997
HEMMI ET AL., NAT IMMUNOL, vol. 3, 2002, pages 196 - 200
HIROTA ET AL., J.MED.CHEM., vol. 45, 2002, pages 5419 - 5422
ISOBE ET AL., BIOORGANIC & MEDICINAL CHEMISTRY, vol. 11, 2003, pages 3641 - 3647
ISOBE ET AL., J.MED.CHEM., vol. 49, 2006, pages 2088 - 2095
ISOBE, J.MED.CHEM., vol. 49, 2006, pages 2088 - 2095
JIN ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16, 2006, pages 4559 - 4563
KURIMOTO ET AL., BIOORGANIC & MEDICINAL CHEMISTRY, vol. 11, 2003, pages 5501 - 5508
KURIMOTO ET AL., J.MED.CHEM., vol. 53, 2010, pages 2964 - 2972
KURIMOTO, BIOORGANIC & MEDICINAL CHEMISTRY, vol. 12, 2004, pages 1091 - 1099
LEE ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 103, 2006, pages 1828 - 1833
LIU Y-J, ANNU. REV. IMMUNOL., vol. 23, 2005, pages 275 - 306
LUND J. M. ET AL., PNAS, vol. 101, 2004, pages 5598 - 5603
NAKAMURA ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 23, 2013, pages 669 - 672
O'NEILL ET AL., NAT REV IMMUNOL, vol. 13, 2013, pages 453 - 460
PRYDE ET AL., R. MED.CHEM.COMMUN., vol. 2, 2011, pages 185 - 189
TAKEDA K. ET AL., ANNU. REV. IMMUNOL., vol. 21, 2003, pages 335 - 76
TANJI ET AL., SCIENCE, vol. 339, 2013, pages 1426 - 1429
WETERINGS ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, 2009, pages 2249 - 2251

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10646566B2 (en) 2015-03-10 2020-05-12 Glaxosmithkline Biologicals S.A. Compositions and uses
US11207404B2 (en) 2015-03-10 2021-12-28 Glaxosmithkline Biologicals Sa Compositions and uses
JP2017222611A (ja) * 2016-06-16 2017-12-21 学校法人上智学院 ピペリジン化合物の製造方法
US10662416B2 (en) 2016-10-14 2020-05-26 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
US11274285B2 (en) 2016-10-14 2022-03-15 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
WO2019193543A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
US11149052B2 (en) 2018-04-06 2021-10-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides
US11292812B2 (en) 2018-04-06 2022-04-05 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotides
WO2019193533A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2'-cyclic dinucleotides
WO2019193542A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
US11788077B2 (en) 2018-04-12 2023-10-17 Precision Biosciences, Inc. Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019200247A1 (en) 2018-04-12 2019-10-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
EP4671244A1 (en) 2018-10-31 2025-12-31 Gilead Sciences, Inc. SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS USED AS HPK1 INHIBITORS
EP4371987A1 (en) 2018-10-31 2024-05-22 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
WO2020092621A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US12318403B2 (en) 2019-03-07 2025-06-03 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides and prodrugs thereof
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020214652A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020214663A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
EP4458416A2 (en) 2019-04-17 2024-11-06 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
EP4458975A2 (en) 2019-09-30 2024-11-06 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
EP4567109A2 (en) 2019-12-06 2025-06-11 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
US12410418B2 (en) 2019-12-06 2025-09-09 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN118165930A (zh) * 2024-04-16 2024-06-11 颖奕干细胞生物科技(海南)有限公司 一种长效维持血液中颗粒球细胞的方法
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus

Also Published As

Publication number Publication date
ES2917887T3 (es) 2022-07-12
US10584125B2 (en) 2020-03-10
MX2017006302A (es) 2018-02-16
US20200223849A1 (en) 2020-07-16
CA2967248A1 (en) 2016-05-19
EP3218377A1 (en) 2017-09-20
BR112017009648A2 (pt) 2017-12-19
BE1023340A1 (fr) 2017-02-08
EP3218377B1 (en) 2022-04-13
BE1023340B1 (fr) 2017-02-08
US20180291026A1 (en) 2018-10-11
CN107108628A (zh) 2017-08-29
JP2017533925A (ja) 2017-11-16
US10919894B2 (en) 2021-02-16

Similar Documents

Publication Publication Date Title
US10919894B2 (en) Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
US10117873B2 (en) 6-amino-purin-8-one compounds
AU2011214468B2 (en) 6-amino-2-{ [ (1S)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8H-purin-8-one maleate
US8575181B2 (en) Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
US20110135671A1 (en) Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
US8575340B2 (en) Purine derivatives and their pharmaceutical uses
WO2010018132A1 (en) Compounds
AU2014271321B2 (en) Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15797460

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2967248

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2017525536

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15526345

Country of ref document: US

Ref document number: MX/A/2017/006302

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017009648

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2015797460

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112017009648

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170508